Poseida Therapeutics Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- Poseida Therapeutics's estimated revenue is currently $14.4M per year.
- Poseida Therapeutics received $30.0M in venture funding in April 2018.
- Poseida Therapeutics's estimated revenue per employee is $144150
- Poseida Therapeutics's total funding is $226.5M.
- Poseida Therapeutics has 100 Employees.
- Poseida Therapeutics grew their employee count by 72% last year.
- Poseida Therapeutics currently has 19 job openings.
|Joshua Rychak||Director (Nanotechnology)|
|Julia Coronella||Senior Director|
|Michelle Resler||Senior Director, Clinical Operations|
|Devon Shedlock||Vice President, Preclinical Development|
|Julian Down||Senior Director of Gene Therapy|
|Joanne McCaigue||Director, Clinical Data Management|
|Glenn Dourado||Vice President, Business Development|
|Jennifer Collins||Vice President, Quality Operations|
|Johanna Mylet||Vice President Finance|
|Danielle Campbell||Director, Human Resources|
What Is Poseida Therapeutics?
Poseida Therapeutics is translating best-in-class gene engineering technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida's lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene engineering technologies, including the piggyBac DNA Modification System, TAL-CLOVER and Cas-CLOVER site-specific nucleases, and Footprint-Free Gene Editing (FFGE). For more information, visit www.poseida.com.keywords:Automotive,Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Advanced Cell D...||$25.7M||178||8%|
|Full Spectrum A...||$6M||42||5%|
Poseida Therapeutics News
More about Poseida Therapeutics: The San Diego-based biopharmaceutical company is developing CAR-T treatments, which harness the ...
SAN DIEGO, April 22, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging ...
Editas and Intellia, like CRISPR Therapeutics, reached 12-month lows .... Poseida Therapeutics, $226.5 million, Novartis Pharma AG invested ...
Poseida Therapeutics Funding
|2015-12-17||$30.0M||A||Malin Corporation plc||Article|
Poseida Therapeutics Executive Hires
|2017-01-04||Debra Gessner||VP Regulatory Affairs||Article|
|2018-02-06||Martin Giedlin||Vice President, Technical Operations||Article|
|2018-03-01||Mark Gergen||chief business officer and chief financial officer.||Article|
|2018-10-10||Marcy Graham||Vice President, Corporate Affairs||Article|